IS THE FUTURE OF PRP ABOUT THE PATIENT, NOT THE PLATELETS?

Could understanding the patient be as important as perfecting the PRP protocol? Claudia McGloin explores.

CLAUDIA MCGLOIN

Claudia McGloin, is a registered nurse with dual registration in Ireland and the UK with more than 28 years of clinical experience. She is one of Ireland’s leading PRP experts, an international speaker, author and educator specialising in regenerative medicine, orthopaedics and medical aesthetics. Through her clinic in Sligo, she has performed thousands of PRP treatments and is committed to advancing education, innovation and patient safety in regenerative healthcare. You can contact Claudia via email: claudiamcgloin@icloud.com

From facial rejuvenation and hair restoration to orthopaedics and sports medicine, clinicians are increasingly embracing autologous therapies to support the body’s natural healing processes.

Much of the conversation surrounding PRP has focused on the product itself.

However, I believe we may be overlooking an equally important factor: the patient.

THE PATIENT BEHIND THE PLATELET CONCENTRATE

Every PRP treatment begins with a blood sample, yet our attention is often directed towards how that blood is processed rather than whether the patient is in the best possible biological state to respond to regenerative treatment.

As clinicians, we know healing is influenced by far more than the procedure itself.

Age, underlying health, inflammation, medications, lifestyle and countless physiological factors all contribute to tissue repair. Yet these variables receive relatively little attention within many discussions surrounding PRP. Take muscle injuries as an example. Most acute muscle injuries recover with appropriate rehabilitation and time. Others become frustratingly persistent despite otherwise appropriate management. While research investigating PRP for muscle injuries has shown encouraging results in some studies, findings remain inconsistent across the literature.

This inconsistency is frequently attributed to differences in PRP preparation systems, platelet concentration and treatment protocols and rightly so. The lack of standardisation continues to challenge both research and clinical practice.

But perhaps another variable deserves equal consideration.

THE BIOLOGY BEHIND THE RESPONSE

Could differences between patients be contributing to the variation we see in outcomes?

Regenerative medicine is founded on biology. If that biology differs significantly from one patient to another, should we really expect identical responses to treatment?

These are not criticisms of PRP. Rather, they are the next questions our profession should be asking.

As regenerative medicine continues to mature, I believe we must move beyond viewing PRP simply as a procedure. Instead, it should be considered part of a broader clinical pathway that begins with careful assessment, informed patient selection and evidence-based decision making.

This does not mean every patient requires extensive investigations or complex protocols. It does mean recognising that successful regenerative medicine is unlikely to rely on the injectable product alone.

Our consultations should remain at the heart of every treatment decision.

The strongest clinicians are not necessarily those who perform the greatest number of procedures, but those who know when treatment is appropriate, when expectations require careful management and when alternative approaches may offer greater benefit.

For aesthetic practitioners, this shift in thinking presents an opportunity.

FROM PROCEDURE TO PATIENT PATHWAY

Patients are becoming increasingly interested in longevity, wellness and regenerative health rather than isolated cosmetic procedures. They are looking for clinicians who understand not only how to perform treatments safely, but how to integrate them into a wider strategy that supports healthy ageing and tissue regeneration.

Perhaps the future of PRP will not be defined solely by advances in technology or the next generation of preparation systems. Perhaps it will be defined by how well we understand the patient sitting in front of us.

Regenerative medicine is evolving rapidly, and with that evolution comes a responsibility to continue questioning, refining and advancing our practice. Standardisation, clinical governance and evidence-based medicine will undoubtedly shape the next chapter of PRP, but so too will a deeper understanding of the factors that influence healing before treatment even begins.

The future of regenerative medicine is not simply about producing better PRP, but about becoming better regenerative clinicians.